Waters Stock News

Waters Corporation ( WAT ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Udit Batra - President, CEO & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you, everybody.

MILFORD, Mass. , Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1 Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environ...

Armstrong World Industries, Inc. (AWI) shares outperformed in the quarter due to beating expectations, driven by favorable positioning in key verticals and strong operating leverage. Somnigroup International Inc. (SGI) was a top performer as it continues to gain incremental share in the bedding market, despite the weakness in the end market. Waters Corporation (WAT) underperformed on the announ...

Waters Corporation ( WAT ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Caspar Tudor - Head of Investor Relations Udit Batra - President, CEO & Director Amol Chaubal - Senior VP & CFO Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Casey Woodring - ...

Lab equipment maker Waters Corp raised its annual profit forecast on Tuesday, after beating third-quarter profit estimates on improved demand from biotech clients for its tools used in drug development and research.

Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidance Instruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growth Recurring revenue grew 9% ...

Sold 243,780 shares for an estimated $85.09 million based on the average price for Q3 2025 The transaction represented a 1.7% change in the fund's reportable assets under management for Q3 2025 Post-sale stake: 0 shares, valued at $0